Prelude Therapeutics (PRLD) Change in Accured Expenses (2019 - 2026)

Prelude Therapeutics has disclosed Change in Accured Expenses across 8 years of filings, most recently posting -$6.6 million for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$6.6 million, down 66.38% year-over-year; the trailing twelve-month figure through Mar 2026 was -$5.6 million (down 712.88% YoY), and the FY2025 annual result was -$3.0 million, down 268.81% from the prior year.
• Change in Accured Expenses came in at -$6.6 million for Q1 2026 at Prelude Therapeutics, down from -$515000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $4.4 million in Q4 2023 to a low of -$6.6 million in Q1 2026.
• The 5-year median for Change in Accured Expenses is $896000.0 (2022), against an average of -$60882.4.
• Across the five-year window, Change in Accured Expenses jumped 583.8% in 2022 and tumbled 389.06% in 2023, its largest moves.
• Prelude Therapeutics' Change in Accured Expenses stood at $3.2 million in 2022, then surged by 38.56% to $4.4 million in 2023, then tumbled by 64.35% to $1.6 million in 2024, then slumped by 132.87% to -$515000.0 in 2025, then plunged by 1181.94% to -$6.6 million in 2026.
• The last three Change in Accured Expenses figures came in at -$6.6 million (Q1 2026), -$515000.0 (Q4 2025), and -$367000.0 (Q3 2025), per Business Quant data.